Myelogenous Leukemia Bcr-abl1 Positive
📧 Sign up to get email alerts when something new happens for Myelogenous Leukemia Bcr-abl1 Positive.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results w…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating donor natural killer cells and donor stem cell transplant in high-risk myeloid malignancies; completed w…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib to prevent acute leukemia after reduced-intensity conditioning and stem cell transplant.
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML [Phase 1, Phase 2]
Phase I/II study evaluating bosutinib combined with inotuzumab ozogamicin in CD22-positive ALL and CML showed completed status with results …
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-02-17Clinical Trial Update: Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant [Phase 2]
Phase 2 clinical trial evaluating treosulfan, fludarabine phosphate, and total-body irradiation as conditioning for umbilical cord blood tra…
-
CLINICAL_TRIALS trial_result · 2020-04-22Clinical Trial Update: Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure [Phase 2]
A Phase 2 trial of bosutinib in chronic myeloid leukemia in chronic phase after frontline TKI failure has been terminated; results posted in…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]
Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib [Phase 2]
Phase 2 trial assessing fludarabine phosphate with total-body irradiation followed by donor peripheral blood stem cell transplant in adults …
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating pentostatin and lymphocyte infusion to prevent graft rejection after donor stem cell transplantation—compl…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]
A Phase 2 study evaluated the combination of Oblimersen with Imatinib Mesylate in patients with chronic myelogenous leukemia, including BCR-…